Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma
暂无分享,去创建一个
R. Spang | A. Rosenwald | W. Klapper | R. Siebert | G. Ott | H. Stein | J. Richter | D. Lenze | D. Hasenclever | M. Loeffler | R. Küppers | M. Hummel | S. Wessendorf | C. Pott | M. Rosolowski | C. Schwaenen | M. Szczepanowski | H. Trautmann | L. Trümper | P. Kluin | Sietse M. Aukema | M. Kreuz | C. Kohler | S. Aukema
[1] J. Briones,et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2013, Haematologica.
[2] R. Spang,et al. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. , 2013, Blood.
[3] A. Rosenwald,et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.
[4] S. Swerdlow,et al. Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas , 2013, The American journal of surgical pathology.
[5] A. Hagemeijer,et al. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B‐cell lymphomas with MYC rearrangement , 2013, Genes, chromosomes & cancer.
[6] J. Briones,et al. MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy , 2013 .
[7] R. Spang,et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing , 2012, Nature Genetics.
[8] Dereje D. Jima,et al. The genetic landscape of mutations in Burkitt lymphoma , 2012, Nature Genetics.
[9] T. Witzig,et al. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. , 2012, Blood.
[10] R. Spang,et al. The cancer stem cell subtype determines immune infiltration of glioblastoma. , 2012, Stem cells and development.
[11] L. Staudt,et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.
[12] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Green,et al. c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells , 2012, Cell.
[14] Charles Y. Lin,et al. Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.
[15] R. Spang,et al. High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas , 2012, International journal of cancer.
[16] K. Young,et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Rosenwald,et al. MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation , 2012 .
[18] M. Routbort,et al. Prognostic value of MYC rearrangement in cases of B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma , 2012, Cancer.
[19] A. Bagg,et al. B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma , 2012 .
[20] R. Spang,et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. , 2012, Blood.
[21] L. Medeiros,et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome , 2012, Modern Pathology.
[22] A. Rosenwald,et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles , 2011, Haematologica.
[23] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[24] Dirk Hasenclever,et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. , 2011, Blood.
[25] R. Siebert,et al. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Philip M Kluin,et al. Double-hit B-cell lymphomas. , 2011, Blood.
[27] Ed Schuuring,et al. Molecular cytogenetics of lymphoma: where do we stand in 2010? , 2011, Histopathology.
[28] Raul Rabadan,et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.
[29] Michael Hummel,et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. , 2010, Blood.
[30] R. Spang,et al. Detection of genomic aberrations in molecularly defined Burkitt’s lymphoma by array-based, high resolution, single nucleotide polymorphism analysis , 2010, Haematologica.
[31] R. Siebert. Mature B‐ and T‐cell neoplasms and Hodgkin lymphoma , 2010 .
[32] L. Colomo,et al. IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas , 2010, The American journal of surgical pathology.
[33] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Matija Snuderl,et al. B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma , 2010, The American journal of surgical pathology.
[35] A. Feller,et al. BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2. , 2009, Anticancer research.
[36] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[37] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[38] W. Klapper,et al. Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma , 2009, Haematologica.
[39] R. Spang,et al. Microarray‐based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status , 2009, Genes, chromosomes & cancer.
[40] R. Siebert,et al. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge , 2008, Leukemia.
[41] I. Miura,et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations , 2009, Leukemia.
[42] A. Rosenwald,et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.
[43] L. Staudt,et al. Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt’s lymphoma , 2008, Haematologica.
[44] R. Spang,et al. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. , 2008, Blood.
[45] R. Spang,et al. Pathway activation patterns in diffuse large B-cell lymphomas , 2008, Leukemia.
[46] L. Staudt,et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma , 2007, Leukemia.
[47] P. Moreau,et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement , 2007, Haematologica.
[48] R. Gascoyne,et al. A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation , 2007, Leukemia.
[49] F. Jardin,et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.
[50] Richard Simon,et al. Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.
[51] R. Spang,et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.
[52] E. Haralambieva,et al. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? , 2006, Human pathology.
[53] R. Siebert,et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. , 2006, The Journal of molecular diagnostics : JMD.
[54] H. Müller-Hermelink,et al. Clinical, Immunophenotypic, and Genetic Analysis of Adult Lymphomas With Morphologic Features of Burkitt Lymphoma , 2005, The American journal of surgical pathology.
[55] Rainer Spang,et al. twilight; a Bioconductor package for estimating the local false discovery rate , 2005, Bioinform..
[56] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[57] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[58] A. Zelenetz,et al. Molecular cytogenetic analysis of genomic instability at the 1q12–22 chromosomal site in B‐cell non‐Hodgkin lymphoma , 2002, Genes, chromosomes & cancer.
[59] Martin J S Dyer,et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci , 2002, International journal of cancer.
[60] R. Gascoyne,et al. Bcl-3/IgH translocation (14;19)(q32;q13) in Non-Hodgkin's Lymphomas , 2002, Leukemia & lymphoma.
[61] M. Neuberger,et al. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line , 2000, Oncogene.
[62] R. Siebert,et al. Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group. , 1999, Blood.
[63] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[64] G. Gaidano,et al. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. , 1994, Blood.